Melanoma Treatment: What Happens When It’s Time for a Different Option?

Starting treatment for melanoma comes with a plan: begin therapy, monitor how the melanoma responds, manage side effects, and continue treatment as long as it is working and remains appropriate.

But melanoma treatment does not always follow a straight line.

Sometimes a treatment stops working. Sometimes new tumors appear. Sometimes treatment is working, but side effects make continuing difficult or unsafe. And sometimes a change in the course of the disease means that a different type of treatment should be considered.

When that happens, one of the first questions patients understandably ask is: What comes next?

The answer is rarely based on one factor. Choosing the next melanoma treatment option is an individualized decision that takes into account the melanoma itself, the treatments you have already received, how you responded to those treatments, your overall health, and your quality of life.

And importantly, needing to change treatment does not mean you have run out of options.

In this webinar, Melissa Wilson, PA-C, MPAS, AIM at Melanoma’s Ask an Expert, explains why melanoma treatments may change, what doctors consider when deciding what comes next, and the treatment options that may be available.

Why Might Treatment Need to Change?

There are two primary reasons a melanoma treatment may need to be changed: the melanoma is progressing, or the treatment is causing adverse effects that make it difficult or unsafe to continue.

Progression may mean existing tumors are consistently growing or new tumors have appeared. Your care team will consider the timing and pattern of those changes rather than necessarily changing treatment because of a single finding.

Treatment may also need to change because of toxicity. Immunotherapies, for example, work by activating the immune system, and that immune response can sometimes affect healthy organs and tissues as well.

The decision to change treatment is therefore not simply a question of whether a drug “worked” or “didn’t work.” Your care team is continually weighing the benefits of treatment against its risks and its effect on you.

What Determines What Comes Next?

There isn’t one standard “next treatment” that is right for every person with melanoma.

When considering another therapy, your melanoma care team may look at questions such as:

• Where is the melanoma located?
• Has it spread to other organs?
• Are there tumors that can be injected directly?
• Are brain metastases present?
• How quickly is the melanoma growing?
• Is it causing symptoms?
• Which treatments have you already received?
• How did the melanoma respond to those treatments?
• Did you experience significant toxicities?
• Does your melanoma have a BRAF mutation?
• What is your current performance status?
• How might a treatment affect your everyday life?

These factors help explain why two people with melanoma that may appear similar on paper can receive different treatment recommendations.

What Treatment Options Might Be Considered?

For many patients with advanced melanoma, immune checkpoint inhibitors are an important part of treatment. Depending on the individual situation, these may be used alone or in combination.

If melanoma progresses following immunotherapy, however, there may still be several treatment approaches to consider.

For patients whose melanoma has an appropriate BRAF mutation, BRAF/MEK targeted therapy may be an option. Different BRAF/MEK combinations can have different toxicity profiles, so a patient’s health history and previous treatment experience may factor into the choice of therapy.

Some patients may also have tumors that can be treated with an injectable therapy. T-VEC is one example of an injectable treatment used for certain accessible melanoma tumors. Melissa also discusses RP1, another injectable therapy, and how the location of a patient’s tumors can influence whether an injectable treatment may be considered.

Radiation can also have a role in selected circumstances, particularly when treating specific areas of disease.

The important point is that melanoma treatment is not always a simple sequence of one drug followed by another. Where the melanoma is located, how it is behaving, what treatments you have already received, and how you are doing overall can all influence what options are considered next.

Where Does TIL Therapy Fit?

Tumor-infiltrating lymphocyte, or TIL, therapy is another treatment option for some patients with advanced melanoma.

TIL therapy begins by removing a tumor and collecting immune cells called tumor-infiltrating lymphocytes from it. These cells are then grown to much larger numbers in a laboratory. The patient receives preparatory chemotherapy before the TIL cells are returned through an infusion, followed by IL-2 to support those cells in the body.

TIL therapy was initially used in patients who had already received multiple previous therapies. In the webinar, Melissa discusses newer real-world data suggesting that patients who receive TIL earlier in their treatment course may also benefit.

Because TIL therapy involves several steps—including tumor collection, manufacturing the TIL product, preparatory treatment, infusion, and supportive therapy—eligibility and timing are important conversations to have with a melanoma specialist.

Clinical Trials Aren’t Just a Last Resort

One misconception about clinical trials is that they should only be considered after every standard treatment option has been exhausted.

That is not necessarily the case.

Clinical trials are how many of today’s melanoma treatments became available in the first place, and trial eligibility can depend on where you are in your treatment journey. Some trials may require participants to have received certain previous treatments, while others may only be available before a patient has received multiple lines of therapy.

That makes clinical trials a conversation worth having throughout treatment—not simply when other options have been exhausted.

Ask your care team whether there are clinical trials that may be appropriate for you and whether participating in a trial now, or preserving eligibility for one later, should be part of your treatment planning.

Quality of Life Belongs in the Treatment Conversation

How you are feeling, how independently you are able to function, other medical conditions you may have, your support system, and how a treatment could affect your daily life all matter.

A treatment that is medically possible is not automatically the right treatment for every patient.

If a therapy requires frequent visits, hospitalization, significant monitoring, or assistance at home, those practical considerations should be part of the discussion. So should potential toxicities and how they may affect the life you are trying to live while receiving treatment.

These aren’t secondary concerns. They are part of making an individualized treatment decision.

Questions to Ask When Your Treatment May Be Changing

If your care team is discussing a different treatment, consider asking:

• Why are we considering changing my current treatment?
• What treatment options are available to me now?
• What factors are most important in deciding among those options?
• Does the location of my melanoma affect my choices?
• Does my melanoma have mutations that affect my treatment options?
• Could an injectable therapy be appropriate for any of my tumors?
• Am I a candidate for TIL therapy?
• Are there clinical trials I should consider now?
• What are the potential toxicities of each option?
• How could each treatment affect my quality of life?
• If a treatment takes time to arrange or manufacture, will I need another therapy while I wait?
• Could a treatment I previously received ever be considered again?

There may not always be one obvious answer. Asking these questions can help you understand not only what your care team is recommending, but why.

A Change in Treatment Is Not the End of the Road

Melanoma treatment has changed dramatically, and patients today may have multiple standard-of-care therapies as well as clinical trial opportunities to consider.

If your melanoma progresses or you can no longer continue your current treatment, the next step is to look carefully at the whole picture: your melanoma, your previous treatments, your health, your quality of life, and the therapies available to you.

Most importantly, ask questions.

Understanding your options can help you participate in decisions about your care and have a more informed conversation with your melanoma treatment team.

Have Questions About Melanoma Treatment?

AIM at Melanoma’s Ask an Expert service gives patients and caregivers an opportunity to ask melanoma-related questions. Melissa Wilson, PA-C, MPAS, serves as AIM’s Ask an Expert and answers questions from patients and caregivers about melanoma, treatment, side effects, and other concerns.

Submit your question through AIM at Melanoma’s Ask an Expert service HERE.

This information is provided for educational purposes and is not intended to replace individualized medical advice. Treatment decisions should be discussed with your melanoma healthcare team.